.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Understanding PARP Inhibition in BRCA-Mutated Breast Cancer

EP. 1: Appropriately Diagnosing and Classifying Breast Cancer

December 4th 2018

EP. 2: Considering Treatment for HER2-Negative Breast Cancer

December 4th 2018

EP. 3: BRCA Mutations in HER2-Negative Breast Cancer

December 4th 2018

EP. 4: BRCA+ Breast Cancer: The Advent of PARP Inhibitors

December 4th 2018

EP. 5: Future Role of PARP Inhibition in BRCA+ Breast Cancer

December 4th 2018

EP. 6: Breaking Down the Nature of Breast Cancer

December 4th 2018

EP. 7: Breast Cancer Diagnosis: Addressing Questions and Concerns

December 4th 2018

EP. 8: Treatment Options for HER2-Negative Breast Cancer

December 4th 2018

EP. 9: Benefit of PARP Inhibitors in BRCA+ Breast Cancer

December 4th 2018

EP. 10: BRCA+ Breast Cancer: Managing Patients on PARP Inhibitors

December 4th 2018

EP. 11: Multidisciplinary Management of Breast Cancer

December 4th 2018

EP. 12: Future Treatment Options for BRCA+ Breast Cancer

December 4th 2018

Latest News

Understanding the Cancer Experience From the Outside Looking In

Educated Patient® Breast Cancer Summit at MBCC Treating Brain Metastases Presentation: March 4, 2023

Kisqali Plus Endocrine Therapy May Reduce Breast Cancer Recurrence Risk

Rybrevant Is Efficacious, Tolerable in EGFR Exon 20-Mutant Lung Cancer

View More Latest News